Design, Synthesis and Biological Evaluation of Histone Deacetylase Inhibitors Based on Pyrrolo[2,3‐ d ]pyrimidine and Pyrrolo[2,3‐ b ]pyridine Scaffolds
ChemMedChem · 2023
DOI: 10.1002/cmdc.202200683 ↗At a glance
Journal article in ChemMedChem, 2023. Written by Nian-Dong Mao and 10 co-authors. Institution: School of Pharmacy, Hangzhou Normal University, Hangzhou, China. Major MEDLINE topics: Histone Deacetylase Inhibitors, Antineoplastic Agents. Cited 6 times so far (Crossref); 44 references. Funded by: National Natural Science Foundation of China, Science and Technology Department of Zhejiang Province.
Abstract (original language)
Histone deacetylases (HDACs) are validated targets for the development of anticancer drugs in epigenetics. We have designed and synthesized a series of novel HDAC inhibitors based on pyrrolo[2,3‐ d ]pyrimidine and pyrrolo[2,3‐ b ]pyridine scaffolds. Compound B3 {( E )‐3‐(4‐(((1‐(7 H ‐pyrrolo[2,3‐ d ]pyrimidin‐4‐yl)piperidin‐4‐yl)amino)methyl)phenyl)‐ N ‐hydroxyacrylamide} exhibits potent inhibitory activity against HDACs 1, 2, 3, 6, and 8 with IC 50 values of 5.2, 6.0, 8.8, 4.4, and 173.0 nM, respectively. It exhibited potent antiproliferative effects against three tumour cell lines (IC 50 values of 0.13, 0.37, and 1.11 μM, against MV‐4‐11, K562, and WSU‐DLCL‐2 cells, respectively) with two‐ to sixfold improvement relative to suberoylanilide hydroxamic acid (SAHA). Mechanistic studies on WSU‐DLCL‐2 cells revealed that B3 exhibits anticancer effects through the induction of G 0 /G 1 ‐phase arrest and promotion of apoptosis. The results of this study warrant further investigation of this compound series for the treatment of hematological malignancy.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- School of Pharmacy, Hangzhou Normal University, Hangzhou, China.
- Key Laboratory of Elemene Class Anti-Cancer Chinese Medicine of Zhejiang Province, Hangzhou, China.
- Engineering Laboratory of Development and Application of Traditional Chinese Medicine from Zhejiang Province, Hangzhou, China.
- t/>Collaborative Innovation Center of Chinese Medicines from, Zhejiang Province, Hangzhou, China.
- Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
- School of Basic Medical Science, Hangzhou Normal University, Hangzhou, China.
ORCID profiles: Xingrui He, Xiang-Yang Ye
Funding
- National Natural Science Foundation of China
- Science and Technology Department of Zhejiang Province
Cite
APA
Mao, N. D., Gao, Y., Dang, X. W., Duan, J. L., Hui, Z., Che, H., Xu, Y., Zhang, H., He, X., Garrido, C., & Ye, X. Y. (2023). Design, Synthesis and Biological Evaluation of Histone Deacetylase Inhibitors Based on Pyrrolo[2,3‐ d ]pyrimidine and Pyrrolo[2,3‐ b ]pyridine Scaffolds. ChemMedChem. https://doi.org/10.1002/cmdc.202200683
Vancouver
Mao ND, Gao Y, Dang XW, Duan JL, Hui Z, Che H, et al. Design, Synthesis and Biological Evaluation of Histone Deacetylase Inhibitors Based on Pyrrolo[2,3‐ d ]pyrimidine and Pyrrolo[2,3‐ b ]pyridine Scaffolds. ChemMedChem. 2023. doi:10.1002/cmdc.202200683
BibTeX
@article{Mao2023,
author = {Mao, Nian-Dong and Gao, Yuan and Dang, Xia-Wen and Duan, Ji-Long and Hui, Zi and Che, Hao and Xu, Yueying and Zhang, Hang and He, Xingrui and Garrido, Carmen and Ye, Xiang-Yang},
title = {Design, Synthesis and Biological Evaluation of Histone Deacetylase Inhibitors Based on Pyrrolo[2,3‐ d ]pyrimidine and Pyrrolo[2,3‐ b ]pyridine Scaffolds},
journal = {ChemMedChem},
year = {2023},
doi = {10.1002/cmdc.202200683}
}
EUVIMED